ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. (SPRY) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
spry · stock forecast · 10 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Hold
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$26.00
Consensus
$25.50
+183.6% upside
Low
$25.00
Median: $25.5 · Last Close: $8.99
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$25.50
183.6% upside
High Target
$26
189.2%
Low Target
$25
178.1%
Current Price
$8.99
as of today
Based on analyst price targets, the SPRY stock price prediction for the next 12 months ranges from $25 to $26. The consensus SPRY price forecast of $25.50 implies 183.6% upside from the current price of $8.99.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $9.32 | ↑ 3.65% |
1-day model range: $9.24–$9.39. Peak: $9.39 (+3.65%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $15 | +63.5% |
| 2028 | $20 | +120.5% |
| 2029 | $24 | +162.9% |
| 2030 | $26 | +190.6% |
| 2031 | — | +207.5% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · SPRY · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-28 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2025-01-14 | Raymond James | Maintains | Strong Buy→Strong Buy |
| 2025-01-13 | Leerink Partners | Maintains | Outperform→Outperform |
| 2024-10-08 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2024-09-20 | Leerink Partners | Maintains | Outperform→Outperform |
| 2024-09-16 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2024-09-09 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2024-08-13 | Raymond James | Upgrade ↑ | Outperform→Strong Buy |
| 2024-03-11 | Wedbush | Maintains | Outperform→Outperform |
| 2024-03-05 | Leerink Partners | Upgrade ↑ | Market Perform→Outperform |
Wall Street analysts have recently issued updated ratings on ARS Pharmaceuticals, Inc. (SPRY) stock. Of the recent 27 rating actions, 2 were upgrades and 6 were downgrades. 10 analysts currently cover SPRY.
Analyst Recommendation Trends
SPRY analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$149M
↓ 66.5% YoY
Revenue Next Year
$274M
↑ 83.2% YoY
EPS This Year
$-1.75
EPS Next Year
$-0.96
↓ 45.4% YoY
EPS ForecastReported vs Estimated
Analysts forecast SPRY EPS of $-1.75 for the current fiscal year, based on estimates from 4 analysts. The SPRY revenue forecast is $149M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The SPRY stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus SPRY price target is $25.50 (+183.6% upside), with an analyst consensus of Hold.
The SPRY short-term stock prediction for tomorrow is $9.32 (+3.65%). The SPRY stock price prediction for 2027 estimates an average of $15. The SPRY stock prediction for 2030 projects a range of $24–$28.
ARS Pharmaceuticals, Inc. trades on NASDAQ under the ticker SPRY. The SPRY stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 40% of covering analysts.
Frequently asked questions
SPRY forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month SPRY price target is $25.50, with a high forecast of $26.00 and a low of $25.00. The median price target is shown in the chart above when available. This implies +183.6% potential upside from the current price of $8.99.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.